The GELA LNH03-6B trial comparing R-CHOP-14 and R-CHOP-21 in DLBCL patients aged 60–80y showed no difference of either regimen [2], but results were criticized due to high treatment-related mortality and low dose intensities in the R-CHOP-14 arm. Here, DDIT3 is linked to diffuse large B-cell lymphoma.